All In Biotech

Drug Trial Radar · NCT03106779

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 233 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

233

Actual

Start

Oct 26, 2017

Primary completion

May 25, 2020

Study completion Dec 4, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of participants with chronic myeloid leukemia - chronic phase (CML-CP) having previously been treated with a minimum of two prior ATP-binding site tyrosine kinase inhibitors (TKIs).

Conditions

  • Chronic Myelogenous Leukemia

Interventions

  • AsciminibDrug

    40 mg tablets was taken orally twice a day (BID)

  • BosutinibDrug

    500 mg tablets was taken orally once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Molecular Response (MMR) Rate at 24 WeeksTime frame: 24 weeks

Locations

88 sites in 25 countries. Site status is shown where the registry gives one.

  • University of Chicago Hospital

    Chicago, Illinois

  • Indiana Blood and Marrow Institute

    Beech Grove, Indiana

  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Dana Farber Cancer Center

    Boston, Massachusetts

  • University of Michigan Clinical Trials Office

    Ann Arbor, Michigan

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Weill Cornell Medicine NY-Presb

    New York, New York

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York

  • Uni Of TX MD Anderson Cancer Cntr

    Houston, Texas

  • Utah Huntsman Cancer Center

    Salt Lake City, Utah

  • Novartis Investigative Site

    Capital Federal, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Murdoch, Western Australia, Australia

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Ostrava, Poruba, Czechia

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Düsseldorf, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Jena, Thuringia, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Jerusalem, Israel

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.